Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
Equity to Asset 0.42
DXR's Equity to Asset is ranked higher than
58% of the 282 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. DXR: 0.42 )
DXR' s 10-Year Equity to Asset Range
Min: 0.42   Max: 0.85
Current: 0.42

0.42
0.85
Interest Coverage 25.28
DXR's Interest Coverage is ranked higher than
67% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.42 vs. DXR: 25.28 )
DXR' s 10-Year Interest Coverage Range
Min: 13   Max: 9999.99
Current: 25.28

13
9999.99
F-Score: 2
Z-Score: 0.60
M-Score: -2.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
Operating margin (%) 172.84
DXR's Operating margin (%) is ranked higher than
100% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.64 vs. DXR: 172.84 )
DXR' s 10-Year Operating margin (%) Range
Min: -766.67   Max: 281.17
Current: 172.84

-766.67
281.17
Net-margin (%) -274.57
DXR's Net-margin (%) is ranked lower than
52% of the 287 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.64 vs. DXR: -274.57 )
DXR' s 10-Year Net-margin (%) Range
Min: -496.96   Max: 858.77
Current: -274.57

-496.96
858.77
ROE (%) -13.26
DXR's ROE (%) is ranked higher than
59% of the 278 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.72 vs. DXR: -13.26 )
DXR' s 10-Year ROE (%) Range
Min: -22.61   Max: 30.74
Current: -13.26

-22.61
30.74
ROA (%) -9.21
DXR's ROA (%) is ranked higher than
58% of the 289 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.87 vs. DXR: -9.21 )
DXR' s 10-Year ROA (%) Range
Min: -12.35   Max: 16.86
Current: -9.21

-12.35
16.86
ROC (Joel Greenblatt) (%) 279.93
DXR's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 288 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 20.54 vs. DXR: 279.93 )
DXR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -959.19   Max: 259.04
Current: 279.93

-959.19
259.04
Revenue Growth (3Y)(%) 4.10
DXR's Revenue Growth (3Y)(%) is ranked higher than
71% of the 262 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.50 vs. DXR: 4.10 )
DXR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -60.3   Max: 38.7
Current: 4.1

-60.3
38.7
» DXR's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DXR Guru Trades in Q4 2013

Jim Simons 47,400 sh (-0.63%)
» More
Q1 2014

DXR Guru Trades in Q1 2014

Jim Simons 47,100 sh (-0.63%)
» More
Q2 2014

DXR Guru Trades in Q2 2014

Jim Simons 47,400 sh (+0.64%)
» More
Q3 2014

DXR Guru Trades in Q3 2014

Jim Simons 47,500 sh (+0.21%)
» More
» Details

Insider Trades

Latest Guru Trades with DXR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 0.70
DXR's P/B is ranked higher than
97% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.52 vs. DXR: 0.70 )
DXR' s 10-Year P/B Range
Min: 0.69   Max: 2.68
Current: 0.7

0.69
2.68
P/S 15.80
DXR's P/S is ranked higher than
50% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.80 vs. DXR: 15.80 )
DXR' s 10-Year P/S Range
Min: 14   Max: 101.65
Current: 15.8

14
101.65
EV-to-EBIT -3.13
DXR's EV-to-EBIT is ranked lower than
58% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.95 vs. DXR: -3.13 )
DXR' s 10-Year EV-to-EBIT Range
Min: -16.2   Max: 5
Current: -3.13

-16.2
5
Shiller P/E 7.10
DXR's Shiller P/E is ranked higher than
99% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 143.42 vs. DXR: 7.10 )
DXR' s 10-Year Shiller P/E Range
Min: 5.93   Max: 52.94
Current: 7.1

5.93
52.94

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.50
DXR's Dividend Yield is ranked lower than
84% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.45 vs. DXR: 0.50 )
DXR' s 10-Year Dividend Yield Range
Min: 0.58   Max: 11.38
Current: 0.5

0.58
11.38
Dividend growth (3y) -51.90
DXR's Dividend growth (3y) is ranked higher than
59% of the 111 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.40 vs. DXR: -51.90 )
DXR' s 10-Year Dividend growth (3y) Range
Min: 0   Max: -20.6
Current: -51.9

Yield on cost (5-Year) 0.04
DXR's Yield on cost (5-Year) is ranked lower than
92% of the 152 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.63 vs. DXR: 0.04 )
DXR' s 10-Year Yield on cost (5-Year) Range
Min: 0.04   Max: 0.85
Current: 0.04

0.04
0.85
Share Buyback Rate 100.00
DXR's Share Buyback Rate is ranked higher than
100% of the 234 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.30 vs. DXR: 100.00 )
DXR' s 10-Year Share Buyback Rate Range
Min: 100   Max: -9.2
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.71
DXR's Price/Tangible Book is ranked higher than
98% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.62 vs. DXR: 0.71 )
DXR' s 10-Year Price/Tangible Book Range
Min: 0.77   Max: 2.64
Current: 0.71

0.77
2.64
Price/Median PS Value 0.49
DXR's Price/Median PS Value is ranked higher than
96% of the 300 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.19 vs. DXR: 0.49 )
DXR' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 8.5
Current: 0.49

0.22
8.5
Earnings Yield (Greenblatt) -31.90
DXR's Earnings Yield (Greenblatt) is ranked lower than
52% of the 285 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.70 vs. DXR: -31.90 )
DXR' s 10-Year Earnings Yield (Greenblatt) Range
Min: 20   Max: 38792.9
Current: -31.9

20
38792.9

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Daxor Corp was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.
» More Articles for DXR

Headlines

Articles On GuruFocus.com
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President Dec 18 2014 
Daxor Corporation Announces a Major Study With the Mayo Clinic Dec 11 2014 
Daxor Corporation Announces Payment of a Dividend Nov 17 2014 
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating Bloo Nov 03 2014 
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn Patient Oct 21 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR Feb 10 2013 
High Yields In Healthcare Sector May 26 2011 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2010 
Daxor Corp Reports Operating Results (10-Q) Aug 13 2010 

More From Other Websites
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President Dec 18 2014
Daxor Corporation Announces A Major Study with the Mayo Clinic Dec 11 2014
Daxor Corporation Announces a Major Study With the Mayo Clinic Dec 11 2014
Daxor Corporation Announces Payment of a Dividend Nov 17 2014
Daxor Corporation Announces Payment of a Dividend Nov 17 2014
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating... Nov 03 2014
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating... Nov 03 2014
Daxor Corporation Announces Research Agreement with Virginia Commonwealth University on Burn... Oct 21 2014
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn... Oct 21 2014
Daxor Corporation Announces Filing of Form N-CSR for June 30, 2014 Aug 29 2014
Daxor to Explore Possible Partnership or Partial Sale of the Company Jun 19 2014
Heart Failure Study From the Mayo Clinic Utilizing Daxor's BVA-100 Blood Volume Analyzer Published... May 30 2014
Daxor Corporation's Idant Laboratories Subsidiary Earns American Association of Blood Banks (AABB)... Apr 30 2014
Dr. Feldschuh, CEO of Daxor, Returned to Work After Fracturing a Hip, Speaks About Extensive Blood... Apr 10 2014
A Little-Known Device That Can Save Your Life Mar 12 2014
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013 Feb 28 2014
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2013 Feb 28 2014
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had... Feb 11 2014
Daxor Corporation Announces Dr. Joseph Feldschuh, President and CEO, Sustained a Fractured Hip, Had... Feb 11 2014
Daxor Announces a Research Study That Proves Micro Samples are Feasible for Accurate Blood Volume... Jan 15 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK